SAB Biotherapeutics Operating Income

The latest operating income for SABS is $-72M as of June 2026. That compares with $-36M in the prior-year period — down 98.6% year over year. Investors often review this figure alongside SAB Biotherapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, SABS's operating income moved from $-36M to $-72M — a 98.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in SAB Biotherapeutics's operating scale or balance-sheet position.

A operating income figure of $-72M for SABS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting SABS's operating income ($-72M), review year-over-year change from $-36M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.